Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
To determine if the acute toxicity of an autologous stem cell transplant with a busulfan/ melphalan (BuMel) based regimen is tolerable when given as Consolidation therapy for high-risk neuroblastoma.
Keywordsautologous, stem cell transplant, consolidation therapy, neuroblastoma, high-risk
Principal InvestigatorWilliam Slayton, M.D.
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.